adverse events, afatinib, dose reduction, non-small cell lung cancer, Adult, Afatinib, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Education, Nursing, Continuing, ErbB Receptors, Female, Humans, Male, Middle Aged, Mutation, Protein Kinase Inhibitors